Skip to content

Zelenectide Pevedotin

Bicycle Therapeutics' Nectin-4-targeting Bicycle Drug Conjugate — a synthetic bicyclic peptide carrying the cytotoxin MMAE, designed as a smaller, faster-clearing alternative to the antibody-drug conjugate enfortumab vedotin. It produced real response rates in metastatic urothelial cancer, and in March 2026 Bicycle deprioritised it anyway, after concluding its registrational trial design was no longer an acceptable approval path.

CModerateLimited Data
Last updated 18 citations
TL;DR

Zelenectide pevedotin is an experimental cancer drug made of a tiny engineered peptide that finds a protein called Nectin-4 on bladder-cancer cells and delivers a cell-killing toxin to them. It shrank tumours in a meaningful share of patients and caused fewer skin and blood-sugar problems than the approved antibody drug it was meant to improve on. In March 2026 its maker stopped prioritising it — not because it failed, but because the standard of care moved and the trial it was running could no longer support approval.

What is Zelenectide Pevedotin?

Zelenectide pevedotin is an investigational cancer therapy from Bicycle Therapeutics, built on a platform the company calls Bicycle Drug Conjugates. It was known throughout its early development as BT8009, and the two names appear interchangeably across the literature, the trial registry and news coverage — including, frequently, in material that confuses it with Bicycle's other conjugate, nuzefatide pevedotin. They are different drugs with different targets. Zelenectide pevedotin targets Nectin-4; nuzefatide pevedotin targets EphA2. The shared second word is not a coincidence: the suffix 'pevedotin' designates the monomethyl auristatin E payload and linker that both molecules carry. The molecule has three parts. The targeting element is a bicyclic peptide — a short synthetic peptide constrained into two loops by a central chemical scaffold, which gives a molecule of roughly 1.5 to 2 kilodaltons the shape-specific binding normally associated with an antibody. It was found by phage display and then rebuilt through medicinal chemistry, including the substitution of non-natural amino acids, to improve plasma stability and physicochemical properties. That peptide is joined through a molecular spacer and a valine-citrulline cleavable linker to monomethyl auristatin E, a microtubule-disrupting cytotoxin far too poisonous to give systemically on its own. The target was chosen because it had already been validated commercially. Nectin-4 is overexpressed in urothelial carcinoma and several other solid tumours, and enfortumab vedotin — an antibody-drug conjugate carrying the same MMAE payload to the same antigen — is an approved and highly effective drug. Bicycle's argument was never that Nectin-4 was a new idea; it was that the delivery vehicle could be better. An antibody is about a hundred times larger than a bicyclic peptide, circulates for days to weeks, penetrates tumour tissue slowly, and carries a toxicity burden — skin reactions, peripheral neuropathy, hyperglycemia — that causes a substantial share of patients to discontinue. A peptide conjugate diffuses out of the bloodstream into tissue rapidly, is cleared renally with a half-life of one to two hours in preclinical species, and in principle delivers toxin to the tumour without bathing the rest of the body in it. The clinical data were consistent with that argument. The drug produced durable responses in urothelial cancer, including a 58% confirmed response rate in combination with pembrolizumab in previously untreated patients, and a notably clean skin and metabolic profile. It did not matter. In March 2026 Bicycle announced a strategic reprioritisation, cut roughly 30% of its workforce, converted the registrational Duravelo-2 trial from Phase 2/3 to a randomised Phase 2, discontinued the breast and lung cancer trials, and deprioritised zelenectide pevedotin for internal development — stating that the existing trial design was no longer considered acceptable as an approval path. The trial continues and survival data are expected in the second half of 2027, but the company is no longer developing the drug as a priority asset.

What Zelenectide Pevedotin Is Investigated For

Zelenectide pevedotin has one indication with real data behind it — metastatic urothelial cancer — and two that were abandoned before they produced any. In urothelial cancer the evidence is genuinely substantial by the standards of a Phase 2 asset. The first-in-human dose escalation, published in the Journal of Clinical Oncology in December 2025, reported an objective response rate of 38% in the urothelial subgroup. The randomised Duravelo-2 trial, presented at ASCO in May 2026, reported a 58% confirmed response rate for the combination with pembrolizumab in 26 previously untreated patients and a 30% confirmed rate for monotherapy in 27 previously treated patients, with three complete responses. Those are credible numbers in a disease where they can be interpreted, and the safety profile is where the drug was most interesting: 17% skin reactions and no hyperglycemia in the combination cohort, against a comparator class in which both are prominent reasons for discontinuation. The breast and lung programmes never got that far. Duravelo-3 in NECTIN4-amplified breast cancer and Duravelo-4 in NECTIN4-amplified non-small cell lung cancer both opened in 2025 and were both discontinued in March 2026 as part of the company-wide reprioritisation — enrollment closed, with patients already on treatment allowed to complete. No efficacy data from either trial have been reported. The preclinical case for both indications was reasonable and the clinical case is simply absent. The broader claim — that a bicyclic peptide can do an antibody's job as a tumour-targeting vehicle — is the one this drug most clearly supports, and it survives the programme's deprioritisation. The responses were real, the tumour penetration argument held up, and the toxicity differentiation showed up where the preclinical work predicted it would. What the programme did not establish is that any of this translates into a regulatory approval, because the trial that was supposed to test that was dismantled before it could.

Metastatic urothelial cancer, first line, with pembrolizumab
Moderate70%
Metastatic urothelial cancer, previously treated, as monotherapy
Moderate70%
A differentiated toxicity profile versus enfortumab vedotin — particularly skin and hyperglycemia
Emerging50%
Proof that a synthetic bicyclic peptide can replace an antibody as a targeting vehicle
Moderate70%
NECTIN4-amplified breast cancer
Limited15%
NECTIN4-amplified non-small cell lung cancer
Limited15%

History & Discovery

Bicycle Therapeutics was founded on chemistry developed in Sir Greg Winter's laboratory at the MRC Laboratory of Molecular Biology in Cambridge — the same laboratory that produced the antibody engineering work for which Winter shared the 2018 Nobel Prize in Chemistry. The bicyclic peptide idea is in a sense a reaction against antibodies: take the phage display technology that made antibody engineering possible, apply it to short peptides constrained by a chemical scaffold, and obtain antibody-like binding in a molecule a hundredth the size that can be made by chemical synthesis rather than cell culture. The Nectin-4 programme began as a deliberate attempt to beat a specific competitor. Enfortumab vedotin, an antibody-drug conjugate delivering MMAE to Nectin-4, had demonstrated striking efficacy in metastatic urothelial cancer. Bicycle's preclinical paper is explicit about the reasoning: enfortumab vedotin produced excellent data in urothelial cancer but little efficacy data in other Nectin-4-expressing tumours, and its toxicities frequently led to discontinuation, so additional approaches with the potential to extend utility and reduce toxicity were warranted. The target was validated; the vehicle was the hypothesis. The binding peptide was found by phage display and then rebuilt. The original hit was selective but unstable in plasma with poor physicochemical properties, and the published optimisation campaign — introducing non-natural amino acids to improve stability and drug-likeness — is what turned a screening hit into a conjugatable molecule. Conjugation to MMAE through a valine-citrulline cleavable linker produced BT8009, and the two defining 2022 papers appeared within weeks of each other in the Journal of Medicinal Chemistry and Molecular Cancer Therapeutics. Duravelo-1, the Phase 1/2 first-in-human study, opened in July 2020. Fast Track designation followed in January 2023 for previously treated locally advanced or metastatic urothelial cancer. The registrational Duravelo-2 trial opened in January 2024 as a Phase 2/3 study, and in 2025 the programme expanded into NECTIN4-amplified breast cancer (Duravelo-3, March 2025) and non-small cell lung cancer (Duravelo-4, July 2025). BT8009 received its International Nonproprietary Name, zelenectide pevedotin, during this period. The reversal came on 17 March 2026. Bicycle announced a strategic reprioritisation focused on BT5528 and next-generation conjugates, a workforce reduction of approximately 30%, and an expected 50% reduction in annual operating expenses that extended its cash runway by roughly two years into 2030. Duravelo-2 was converted from a Phase 2/3 registrational trial to a randomised Phase 2; Duravelo-3 and Duravelo-4 were discontinued; and zelenectide pevedotin was deprioritised for internal development. The company's stated reason was not efficacy or safety but regulatory: the existing trial design was no longer considered an acceptable approval path. Two months later, Bicycle presented the initial randomised Duravelo-2 data at ASCO — a 58% confirmed response rate in combination with pembrolizumab in previously untreated patients — for a programme it had already stepped back from. The sequence is the lesson. This is a drug whose published response rates look competitive, whose safety profile differentiated in exactly the ways its preclinical pharmacology predicted, and which was nevertheless shelved because the standard of care it was designed to displace moved faster than the trial could. An independent review had named the problem in May 2025. The company confirmed it in March 2026. Survival data are expected in the second half of 2027.

How It Works

Cancer cells in bladder and some other tumours display a protein called Nectin-4 on their surface. Zelenectide pevedotin is a tiny engineered peptide that sticks to Nectin-4, carrying a powerful cell-killing toxin attached by a chemical link designed to break apart inside tumour tissue. Because the peptide is about a hundred times smaller than an antibody, it leaves the bloodstream and soaks into the tumour quickly, then washes out through the kidneys within hours — delivering the toxin where it is needed without leaving it circulating through the rest of the body for weeks.

Zelenectide pevedotin consists of a Nectin-4-binding bicyclic peptide joined through a molecular spacer and a valine-citrulline cleavable linker to monomethyl auristatin E. Each element carries a specific design burden. The bicyclic peptide was identified by phage display and then substantially re-engineered. The original screening hit bound Nectin-4 with high selectivity but had poor plasma stability and unfavourable physicochemical properties — the standard problem with peptides from a display library. Multiparameter chemical optimisation, including the introduction of non-natural amino acids, produced a lead with high affinity, stability in biological matrices and a drug-like profile. The bicyclic architecture is what makes a molecule this small behave like a binder: a short peptide constrained into two loops around a central scaffold adopts a defined three-dimensional conformation, which converts weak, promiscuous binding into high-affinity, shape-specific recognition. The resulting molecule is roughly 1.5 to 2 kilodaltons against an antibody's 150. The valine-citrulline linker is a protease-cleavable dipeptide motif that is stable in plasma and cleaved by cathepsin B and related proteases in the tumour environment, releasing free MMAE. MMAE itself is a synthetic auristatin that binds tubulin and blocks microtubule polymerisation, arresting cells in mitosis and triggering apoptosis. It is cell-permeant once released, which means it can kill neighbouring tumour cells that do not themselves express the target — the bystander effect — and it is also why the molecule's activity does not strictly depend on internalisation by the target cell, a point the review literature has emphasised as a difference from classical antibody-drug conjugates. The pharmacokinetics are the real argument for the platform. In rats and non-human primates the intact conjugate has a plasma half-life of one to two hours and is eliminated renally. A small hydrophilic peptide diffuses out of the systemic circulation through tissue rapidly, reaching tumour cells within minutes rather than over the days an antibody requires. Bicycle's framing is 'fast in, fast out': rapid tumour uptake followed by fast clearance of the parent drug, leaving persistent toxin concentrations inside the tumour without prolonged exposure of the vasculature and normal tissue to circulating conjugate. In preclinical models this produced antitumour activity superior or equivalent to an enfortumab vedotin analog across a range of indications while being well tolerated in safety studies. Whether that translated to humans is partly answerable. The clinical toxicity profile did diverge from the comparator class in the directions predicted: skin reactions were present but not severe, and hyperglycemia — a distinctive and sometimes dangerous enfortumab vedotin toxicity — was absent in the combination cohort and occurred in 3% of the monotherapy cohort. Peripheral neuropathy, by contrast, occurred at rates of 33 to 38%, which is squarely in the range expected for any MMAE-based agent and suggests the payload's class effects are not avoided by changing the vehicle. The short half-life also imposes a practical cost: dosing schedules ran weekly or on a two-weeks-on, one-week-off cycle rather than the every-three-weeks cadence an antibody permits.

Evidence Snapshot

Overall Confidence55%

Human Clinical Evidence

One peer-reviewed Phase 1 dataset, one randomised Phase 2 dataset reported only in company disclosures, and two discontinued trials with no results. The published first-in-human monotherapy dose escalation from Duravelo-1 (NCT04561362), in the Journal of Clinical Oncology in December 2025, enrolled 49 patients — 25 with urothelial carcinoma, a median of three prior lines of therapy — across doses of 2.5, 5.0 and 7.5 mg/m2 weekly, 7.5 mg/m2 on days 1 and 8 of a 21-day cycle, and 7.5 or 10.0 mg/m2 every two weeks. The maximum tolerated dose was 7.5 mg/m2 every two weeks and the recommended Phase 2 doses were 5.0 mg/m2 weekly and 7.5 mg/m2 on days 1 and 8 of a 21-day cycle. Across all tumour types the objective response rate was 24% (10 of 42 efficacy-evaluable; 95% CI 12.1 to 39.5) with a clinical benefit rate of 48%; in the urothelial subgroup the response rate was 38% (8 of 21; 95% CI 18.1 to 61.6) with a clinical benefit rate of 57%. Median duration of response was 11.1 months against a median follow-up of 7.4 months. The randomised Duravelo-2 data presented at ASCO in May 2026 have not been peer-reviewed: in previously untreated metastatic urothelial cancer, zelenectide pevedotin at 6 mg/m2 on a two-weeks-on, one-week-off schedule with pembrolizumab produced a blinded-central-review confirmed response rate of 58% (15 of 26), rising to 62% (16 of 26) after the data cutoff, with 65% of patients still on treatment at a median treatment duration of 6.3 months; in previously treated patients, monotherapy produced a confirmed response rate of 30% (8 of 27) including three complete responses. Duravelo-3 in breast cancer and Duravelo-4 in non-small cell lung cancer were discontinued in March 2026 without reporting.

Animal / Preclinical

The preclinical package, published across two 2022 papers in the Journal of Medicinal Chemistry and Molecular Cancer Therapeutics, is unusually direct about the comparison that mattered. BT8009 showed significant antitumour activity across multiple cancer indications in rodent models and, in several of them, activity superior or equivalent to an enfortumab vedotin analog — a company-run comparison against a surrogate rather than the marketed product, which is the appropriate caveat, but a comparison that was at least attempted. The pharmacokinetic characterisation is the more durable contribution: a half-life of one to two hours in rat and non-human primate with renal elimination, rapid diffusion from circulation into tumour tissue, and tolerability in preclinical safety studies. These physical properties were presented as the differentiator from antibody-drug conjugates, and the clinical toxicity profile later matched the prediction in the dermatological and metabolic domains while not avoiding MMAE's neurological class effect.

Mechanistic Rationale

Strong, and validated at both ends. Nectin-4 was already a commercially proven target when the programme began — enfortumab vedotin had demonstrated striking efficacy in metastatic urothelial cancer — so the mechanism carried no target risk. The bicyclic peptide platform risk was the real question, and the clinical data substantially answered it: a 1.5 to 2 kilodalton synthetic peptide delivered enough MMAE to produce confirmed responses in roughly a third to a half of urothelial patients depending on line and regimen, with durability measured in months. The rationale that the format would improve tolerability held in the specific places preclinical pharmacokinetics predicted. What the rationale could never address is the commercial and regulatory problem that ended the programme, which had nothing to do with mechanism.

Research Gaps & Open Questions

What the current literature has not yet settled about Zelenectide Pevedotin:

  • 01Whether zelenectide pevedotin is better, worse or equivalent to enfortumab vedotin plus pembrolizumab. No head-to-head trial exists or is planned, and the deprioritisation means none is likely — which leaves the drug's central claim permanently untested.
  • 02Whether NECTIN4 amplification predicts response outside urothelial cancer. The breast and lung trials were discontinued before reporting any efficacy data, so the hypothesis that drove them is unresolved.
  • 03What the Duravelo-2 survival data show. Bicycle expects to report overall survival from the randomised Phase 2 in previously untreated metastatic urothelial cancer in the second half of 2027; response rates without survival do not establish benefit.
  • 04Whether the apparent dermatological and metabolic advantage over enfortumab vedotin is real or an artefact of cross-trial comparison across different populations and lines of therapy.
  • 05Long-term cumulative peripheral neuropathy with extended dosing. Median treatment duration in the randomised cohorts was 4.8 to 6.3 months, which is too short to characterise the toxicity most likely to limit the drug over time.
  • 06Whether the bystander effect and internalisation-independent activity described in the review literature contribute materially to clinical efficacy, or are preclinical observations without a demonstrated clinical correlate.
  • 07Dosing in renal impairment, given renal elimination of the conjugate and the absence of any dedicated study.
  • 08Whether a partner or acquirer takes the asset forward. Bicycle has said it is evaluating next steps rather than terminating the programme, and the drug's eventual fate is a commercial question rather than a scientific one.

Forms & Administration

Zelenectide pevedotin is given by intravenous infusion in an oncology clinic. There is no other route, and there could not be — it is a cytotoxic conjugate requiring controlled administration, dose calculation by body surface area, and monitoring for infusion reactions and myelosuppression. Dosing in the trials has been expressed in mg/m2 and the schedules have varied more than is usual, which is a direct consequence of the molecule's short half-life. Dose escalation explored once-weekly dosing on a 28-day cycle, days 1 and 8 of a 21-day cycle, and once every two weeks on a 28-day cycle. The recommended Phase 2 doses from that study were 5.0 mg/m2 once weekly and 7.5 mg/m2 on days 1 and 8 of a 21-day cycle. The randomised Duravelo-2 trial settled on 6 mg/m2 given two weeks on and one week off as the optimal dose, with pembrolizumab 200 mg every three weeks in the combination cohort. A drug with a one-to-two-hour parent half-life cannot be given every three weeks the way an antibody-drug conjugate can, and the resulting infusion burden is a genuine practical cost of the platform. No oral, subcutaneous or compounded form exists in any form, and the compound is not available outside a clinical trial.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

5.0–7.5 mg/m2 intravenously in Phase 1; 6 mg/m2 selected as the optimal dose in Duravelo-2

Frequency

Weekly, days 1 and 8 of a 21-day cycle, or two weeks on and one week off, depending on the study

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Protocol Notes

These are trial doses for an investigational intravenous chemotherapy conjugate, recorded so the published results can be read accurately. There is no prescribable dose and no setting outside an oncology trial in which this drug is administered. The dose-escalation study explored an unusually wide range of schedules because the molecule's short half-life made the right cadence genuinely uncertain: 2.5, 5.0 and 7.5 mg/m2 once weekly on a 28-day cycle; 7.5 mg/m2 on days 1 and 8 of a 21-day cycle; and 7.5 or 10.0 mg/m2 once every two weeks on a 28-day cycle. The maximum tolerated dose was 7.5 mg/m2 every two weeks, and two recommended Phase 2 doses emerged — 5.0 mg/m2 weekly and 7.5 mg/m2 on days 1 and 8 of a 21-day cycle. The randomised Duravelo-2 trial ultimately selected 6 mg/m2 on a two-weeks-on, one-week-off schedule as its optimal dose, given with pembrolizumab 200 mg every three weeks in the first-line combination cohort. The schedule complexity is not incidental. An antibody-drug conjugate with a multi-day half-life can be given every three weeks; a conjugate whose parent molecule clears in one to two hours cannot. Frequent infusion is the price of the fast-in, fast-out pharmacokinetics that produce the toxicity differentiation, and it is a real burden on patients and infusion centres that any assessment of the platform has to weigh against the safety advantage.

Zelenectide pevedotin is an investigational intravenous cytotoxic agent with no marketing approval anywhere. It is administered only in clinical trials under oncology supervision with haematological monitoring.

Timeline of Effects

Onset

Pharmacokinetically immediate and brief — the conjugate distributes out of the circulation into tissue within minutes and the parent molecule clears with a half-life of one to two hours in preclinical species, leaving MMAE to act within the tumour. Clinically, response is assessed radiographically on the trial schedule, typically every eight weeks for the first year in Duravelo-1. No earlier marker of activity has been reported.

Peak Effect

Median duration of response in the published dose escalation was 11.1 months against a median follow-up of 7.4 months, meaning the response durability estimate was not yet mature. In the randomised first-line combination cohort, median treatment duration was 6.3 months with a range of 0.7 to 10.6 months and 65% of patients still receiving treatment at the data cutoff; in the previously treated monotherapy cohort, median treatment duration was 4.8 months with 31% still on treatment. These are treatment durations rather than response durations and should not be read as the latter.

After Discontinuation

Not characterised, and the relevant question is not withdrawal but residual toxicity. MMAE-associated peripheral neuropathy is cumulative and can persist or worsen for a period after the last dose before improving, which is the pattern with every auristatin conjugate; no peptide-specific data on resolution have been published. The drug itself leaves the circulation within hours, so there is no pharmacological tail from the conjugate.

Common Questions

Is zelenectide pevedotin the same thing as BT8009?

Yes. BT8009 was the development code; zelenectide pevedotin is the International Nonproprietary Name adopted later. Older papers, posters and registry entries use BT8009, and the trial identifiers still carry it — the registrational study is registered as BT8009-230. The name worth being careful about is the other one: nuzefatide pevedotin, formerly BT5528, is a different Bicycle conjugate that targets EphA2 rather than Nectin-4 and is in trials for pancreatic cancer. News coverage has repeatedly swapped the two. If a report mentions bladder cancer and the Duravelo trials, it concerns zelenectide pevedotin; if it mentions EphA2 or pancreatic cancer, it concerns nuzefatide pevedotin.

Why was it deprioritised if the response rates were good?

Because the comparator moved. Duravelo-2 was designed as a registrational Phase 2/3 trial with a control arm of platinum-based chemotherapy with or without avelumab maintenance — the first-line standard when the trial was written. By the time it was running, enfortumab vedotin plus pembrolizumab had become the first-line standard of care in metastatic urothelial cancer, which made the control arm obsolete. An independent review in Expert Opinion on Investigational Drugs flagged exactly this in May 2025, criticising 'the use of outdated control arms and the lack of direct comparisons to EV.' Ten months later Bicycle said in its own words that 'the existing Duravelo-2 trial design is no longer considered acceptable as an approval path for zelenectide in mUC.' Running the trial again against the correct comparator would have meant years and a great deal of money, which is the decision the company declined to make.

How does it differ from enfortumab vedotin?

Same target, same payload, completely different vehicle. Enfortumab vedotin is a monoclonal antibody — roughly 150 kilodaltons, circulating for days, penetrating tumour tissue slowly, internalised by the target cell. Zelenectide pevedotin is a bicyclic peptide of roughly 1.5 to 2 kilodaltons that diffuses rapidly out of the circulation into tissue, is eliminated renally rather than hepatically, and has a plasma half-life of one to two hours in rats and primates. Bicycle described the resulting profile as 'fast in, fast out': the toxin accumulates in tumour without prolonged systemic exposure to the parent drug. The clinical consequence that showed up most clearly was dermatological — in the Duravelo-2 combination cohort, skin reactions occurred in 17% of patients with no severe skin reactions of any grade reported, and no hyperglycemia, both of which are well-known problems with enfortumab vedotin. No head-to-head trial has ever been run, so this comparison rests on cross-trial observation.

What is a bicyclic peptide and why use one instead of an antibody?

A bicyclic peptide is a short synthetic peptide chemically constrained into two loops by a central scaffold. The constraint is what makes it work: an unconstrained short peptide is floppy, binds weakly and is degraded quickly, whereas locking it into a defined three-dimensional shape produces the kind of high-affinity, shape-specific binding normally associated with a much larger protein. The advantages over an antibody are size and chemistry. It is fully synthetic, so it is manufactured by chemical synthesis rather than cell culture; it is small enough to leave the bloodstream and penetrate tumour tissue quickly; and it is cleared through the kidney within hours rather than persisting for weeks. The disadvantages are the mirror image: the short half-life means frequent dosing, and there is no Fc region, so none of the immune-mediated effects an antibody can contribute are available.

Can a patient get zelenectide pevedotin today?

Only through a clinical trial, and the options are narrowing. Duravelo-1 and Duravelo-2 are both listed as active but no longer recruiting. The breast and lung trials were discontinued in March 2026. Bicycle has registered a continued-access protocol (NCT07681674) covering participants already receiving zelenectide pevedotin, BT7480 or nuzefatide pevedotin on a company-sponsored study — a mechanism for keeping existing patients on drug after a parent trial closes, not a route for new patients. The drug is not approved in any country and there is no expanded-access programme listed for new enrollment.

Does it have any FDA designations?

Fast Track designation, granted in January 2023, for use as a monotherapy in adults with previously treated locally advanced or metastatic urothelial cancer. Bicycle's FY2025 annual report confirms the designation is held, and separately confirms that nuzefatide pevedotin also holds Fast Track in urothelial cancer. Fast Track provides more frequent FDA interaction and eligibility for rolling review; it does not accelerate approval by itself, and it has no bearing on the trial-design problem that caused the programme to be deprioritised. A claim in one 2026 analytical chemistry paper that the drug holds Fast Track for bladder, breast and lung cancers is not supported by any company announcement or filing found in the public record — only the urothelial designation is documented.

Is the Duravelo-2 trial still running?

Yes, as a randomised Phase 2 rather than the Phase 2/3 registrational trial it was designed to be. It is active and no longer recruiting, with estimated primary completion in March 2028. Bicycle stated in its third-quarter 2026 release, dated 29 October 2026, that it expects to report Duravelo-2 survival data from the randomised Phase 2 in previously untreated metastatic urothelial cancer in the second half of 2027. Survival data from a deprioritised asset still matter: they are what a prospective partner or acquirer would price, and Bicycle has said it is evaluating next steps rather than terminating the programme.

Who Zelenectide Pevedotin Is NOT For

Contraindications
  • •Anyone without a Nectin-4-expressing malignancy — this is targeted cytotoxic chemotherapy, not a therapy with any use outside oncology
  • •Pregnancy and breastfeeding; MMAE is a microtubule inhibitor and is expected to be embryotoxic
  • •Pre-existing moderate or severe peripheral neuropathy, where an MMAE-based agent would be expected to worsen it
  • •Significant neutropenia or other haematological compromise at baseline, given a 16% rate of grade 3/4 neutropenia in dose escalation
  • •No paediatric data exist; all trials have enrolled adults only
  • •Renal impairment has not been characterised in a dedicated study, and the conjugate is renally eliminated — a theoretically important gap that the published record does not address

Drug & Supplement Interactions

The only combination studied systematically is with pembrolizumab, and that combination is the basis of the first-line Duravelo-2 cohort rather than an interaction concern. At 6 mg/m2 on a two-weeks-on, one-week-off schedule with pembrolizumab 200 mg every three weeks, the safety profile did not show the overlapping toxicity that might have been feared: skin reactions occurred in 17% with no severe reactions of any grade, and only one patient at the optimal dose discontinued because of a zelenectide-related adverse event. Dose de-escalation cohorts for the combination were built into Duravelo-1, which is the appropriate way to establish that two agents can be given together. Beyond that, interaction data are essentially absent, and the mechanistically relevant question concerns MMAE rather than the peptide. Released MMAE is a substrate for CYP3A4 and for P-glycoprotein, so strong CYP3A4 inhibitors or inducers and P-gp modulators would be expected to alter free MMAE exposure — the standard caution for every auristatin conjugate. No dedicated interaction study for this compound has been published, so that expectation is extrapolated from the payload class rather than measured. Two additive-toxicity considerations follow from the pharmacology. Other agents that cause peripheral neuropathy — taxanes, platinum compounds, vinca alkaloids — would be expected to compound the 33 to 38% neuropathy rate seen with this drug. Myelosuppressive chemotherapy would be expected to compound the neutropenia. Neither has been formally studied, and in practice sequencing rather than combination is how oncology manages both.

Safety Profile

Safety Information

Common Side Effects

Nausea — 49% in the dose-escalation cohort, grade 3/4 in 2%; the investigators attributed the high rate partly to the absence of prophylactic antiemetics during the dose-limiting toxicity windowFatigue — 39%, grade 3/4 in 6%Peripheral neuropathy — 33% in dose escalation (grade 3/4 2%), 33% in the randomised combination cohort, 38% in the randomised monotherapy cohort; an expected class effect of MMAENeutropenia — 22% in dose escalation, grade 3/4 in 16%, the most clinically significant haematological toxicitySkin reactions — 22% in dose escalation (grade 3/4 2%), 17% in the randomised combination cohort with no severe reactions of any grade reported, 28% in the randomised monotherapy cohortEye disorders — 10% in both randomised cohorts

Cautions

  • • This is an intravenous cytotoxic chemotherapy conjugate administered in an oncology setting, not a wellness peptide; the payload is a microtubule inhibitor that would be lethal if given unconjugated at these doses
  • • Peripheral neuropathy is cumulative with MMAE-based agents and is the toxicity most likely to limit long-term dosing
  • • Neutropenia at grade 3 or above occurred in 16% of dose-escalation patients, requiring blood count monitoring
  • • Total clinical exposure remains modest — 49 patients in the published dose escalation, 53 in the two randomised Duravelo-2 cohorts reported at ASCO 2026 — and no full randomised dataset has been peer-reviewed
  • • The comparative safety advantage over enfortumab vedotin rests entirely on cross-trial comparison; no head-to-head study has been conducted

What We Don't Know

The programme's deprioritisation means several things will probably never be known. No randomised comparison against the current standard of care exists or is planned, so the central efficacy question — whether this drug is better, worse or equivalent to enfortumab vedotin plus pembrolizumab — is unanswerable from the data that will be generated. The breast and lung trials were stopped before reporting, so whether NECTIN4 amplification predicts response outside urothelial cancer is unresolved. Long-term safety beyond the median 6.3 months of treatment reported in the combination cohort is uncharacterised, as is cumulative neuropathy risk with extended dosing. Survival data from Duravelo-2 are expected in the second half of 2027 and will be the last substantial readout unless a partner takes the asset forward.

Myths & Misconceptions

Myth

Zelenectide pevedotin failed its clinical trials.

Reality

It did not. It produced a 38% response rate in urothelial cancer in the published dose escalation and a 58% confirmed response rate in combination with pembrolizumab in previously untreated patients in the randomised trial, with a notably clean skin and metabolic profile. What happened is different and more specific: the first-line standard of care shifted to enfortumab vedotin plus pembrolizumab while the trial was running, which made Duravelo-2's platinum-chemotherapy control arm obsolete. Bicycle's own words were that the design 'is no longer considered acceptable as an approval path.' The drug was not beaten in a trial; it was outrun by the field.

Myth

It is the same drug as nuzefatide pevedotin, or a newer version of it.

Reality

They are different molecules with different targets and different development paths. Zelenectide pevedotin, formerly BT8009, targets Nectin-4 and was studied in the Duravelo trials in bladder, breast and lung cancer. Nuzefatide pevedotin, formerly BT5528, targets EphA2 and is now in a Phase 2 trial in pancreatic cancer. The shared 'pevedotin' stem reflects the shared MMAE payload and linker, not a shared targeting element. This confusion is common enough in news coverage that it is worth checking any report against the target or the trial name before relying on it.

Myth

Because it is a peptide rather than an antibody, it avoids chemotherapy toxicity.

Reality

It avoids some of it and not the part that matters most for long-term dosing. The payload is monomethyl auristatin E, the same cytotoxin enfortumab vedotin carries, and the toxicities that come from the payload rather than the vehicle came along with it: peripheral neuropathy in 33 to 38% of patients and grade 3/4 neutropenia in 16% of the dose-escalation cohort. What did appear to differentiate were the toxicities more associated with prolonged systemic exposure to the intact conjugate — skin reactions were present but not severe, and hyperglycemia was essentially absent. Changing the delivery vehicle changed the distribution of harm, not its existence.

Myth

Fast Track designation means the FDA was close to approving it.

Reality

Fast Track is granted early, on the basis that a drug treats a serious condition and addresses an unmet need. It provides more frequent meetings with the agency and eligibility for rolling review; it does not lower the evidentiary bar, does not imply the agency has assessed efficacy, and is routinely granted to compounds that never reach the market. Zelenectide pevedotin held Fast Track from January 2023 and was deprioritised in March 2026 over a trial-design problem the designation had no bearing on.

Myth

Bicycle shut the programme down.

Reality

Deprioritised is not terminated, and the distinction matters for reading future news. Duravelo-2 continues as a randomised Phase 2 with survival data expected in the second half of 2027, and Bicycle stated it was evaluating next steps. What the company stopped was internal investment at priority level and the two expansion trials in breast and lung cancer. Resources moved to nuzefatide pevedotin, which received Orphan Drug Designation for pancreatic cancer in September 2026, and to the company's radioconjugate platform.

Published Research

18 studies

The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates

ReviewPMID: 42240280

The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents

ReviewPMID: 41861349

From Cloudy to Clear: A Strategy to Resolve the Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR

Analytical ChemistryPMID: 41553133

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

The pivotal published dataset, in the Journal of Clinical Oncology, December 2025. Forty-nine patients, 25 with urothelial carcinoma, median three prior lines. Establishes the maximum tolerated dose of 7.5 mg/m2 every two weeks and the recommended Phase 2 doses, and reports an overall objective response rate of 24% (10 of 42 evaluable; 95% CI 12.1–39.5) with 38% (8 of 21; 95% CI 18.1–61.6) in the urothelial subgroup and a median duration of response of 11.1 months. The source for the safety profile: nausea 49%, fatigue 39%, peripheral neuropathy 33%, neutropenia 22% with 16% grade 3/4, skin reactions 22%.

Phase 1/2 Clinical TrialPMID: 41197088

Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules

ReviewPMID: 41164107

Precision on Two Wheels — Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging

Preclinical / ImagingPMID: 41081542

Design, synthesis and antitumor evaluation of a novel nectin-4 targeting bicyclic toxin conjugate

PreclinicalPMID: 40505992

Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer

An independent review in Expert Opinion on Investigational Drugs, May 2025, from a group at San Raffaele with no Bicycle authorship. Notable for predicting the programme's failure mode ten months before it happened: it praised the clinical profile but warned that the ongoing trial designs raised concerns 'particularly due to the use of outdated control arms and the lack of direct comparisons to EV,' and that these limitations 'could delay its clinical adoption and regulatory approval.' In March 2026 Bicycle stated the Duravelo-2 design was no longer an acceptable approval path.

Independent ReviewPMID: 40401457

The validation and clinical bioanalysis of the Bicycle Toxin Conjugate zelenectide pevedotin in human plasma

Bioanalytical MethodPMID: 39829185

Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

The discovery paper in the Journal of Medicinal Chemistry, 2022. Documents that the Nectin-4-binding bicyclic peptide came from phage display and that the original hit bound selectively but had low plasma stability and poor physicochemical properties, requiring multiparameter optimisation with non-natural amino acids before conjugation to MMAE through a cleavable linker. Important as the primary record of what the molecule actually is, against secondary coverage that routinely describes it simply as a peptide.

Preclinical / Medicinal ChemistryPMID: 36204777

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

The preclinical characterisation in Molecular Cancer Therapeutics, 2022, and the source of the platform's central pharmacokinetic claim: a half-life of one to two hours in rat and non-human primate, renal elimination, and rapid diffusion from circulation into tumour tissue. Reports activity superior or equivalent to an enfortumab vedotin analog in several models — a sponsor-run comparison against a surrogate, not the marketed product. States explicitly that the aim was to extend utility beyond urothelial cancer and reduce the toxicities that cause enfortumab vedotin discontinuation.

PreclinicalPMID: 36112771

NCT04561362 — Duravelo-1, Phase 1/2 study of BT8009 in Nectin-4 expressing advanced malignancies

Clinical Trial Registry

NCT06225596 — Duravelo-2, randomized study of BT8009 in locally advanced or metastatic urothelial cancer

The registrational trial, and the record that shows what happened to it. The official title still reads 'A Randomized Open-Label Phase 2/3 Study,' while the registry's phase field now lists Phase 2 only — the trace of the March 2026 conversion. Confirms the control arm as platinum-based combination chemotherapy with or without avelumab maintenance, which is the design feature that became unacceptable once enfortumab vedotin plus pembrolizumab became first-line standard of care. Status is active, not recruiting, with estimated primary completion in March 2028.

Clinical Trial Registry

NCT06840483 — Duravelo-3, Phase 2 study of zelenectide pevedotin in NECTIN4-amplified advanced breast cancer

Clinical Trial Registry

NCT06933329 — Duravelo-4, Phase 2 study of zelenectide pevedotin in NECTIN4-amplified advanced NSCLC

Clinical Trial Registry

NCT07681674 — Bicycle Continued Access Protocol (BiCAP) for participants receiving a Bicycle investigational product

Clinical Trial Registry

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (SEC Form 8-K exhibit, 17 March 2026)

The release that ended the programme's priority status, and the primary source for every claim on this page about the reprioritisation. States that 'the existing Duravelo-2 trial design is no longer considered acceptable as an approval path for zelenectide in mUC' and that the company 'reached the difficult decision to deprioritize this program for internal development at this time.' Also announces the conversion of Duravelo-2 to a randomised Phase 2, the discontinuation of the Duravelo-3 breast and Duravelo-4 lung trials with enrollment closed and enrolled patients completing treatment, a workforce reduction of approximately 30%, an expected reduction in annual operating expenses of approximately 50%, and a cash runway extended by roughly two years into 2030.

Company Disclosure

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting (SEC Form 8-K exhibit, 21 May 2026)

The source for all randomised Duravelo-2 efficacy and safety figures on this page, which have not been peer-reviewed. Cohort 1, previously untreated metastatic urothelial cancer at the optimal dose of 6 mg/m2 two weeks on and one week off with pembrolizumab 200 mg every three weeks: confirmed response rate by blinded central review 58% (15 of 26) at the 27-week cutoff, 62% (16 of 26) after cutoff, median treatment duration 6.3 months, 65% still on treatment, peripheral sensory neuropathy 33%, skin reactions 17%, eye disorders 10%, no hyperglycemia, no severe skin reactions of any grade. Cohort 2, previously treated monotherapy: confirmed response rate 30% (8 of 27) with 3 complete and 5 partial responses, no discontinuations at the optimal dose.

Company Disclosure

Quick Facts

Class
Bicyclic Peptide-Drug Conjugate (Nectin-4 / MMAE)
Tier
C
Evidence
Moderate
Safety
Limited Data
Updated
Nov 2026
Citations
18PubMed

Also known as

BT8009BT-8009ZelenectideBicycle Toxin Conjugate BT8009

Tags

InvestigationalOncologyBicycle Drug ConjugateNectin-4MMAEUrothelial CancerDeprioritizedBicycle Therapeutics

Evidence Score

Overall Confidence55%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.